Alnylam Pharmaceuticals, Inc. (ALNY) Financials
Key financial figures for Alnylam Pharmaceuticals, Inc. (Q2 2026).
Alnylam Pharmaceuticals, Inc. reported revenue of $1.29 billion for Q2 FY2026, up 66.9% from the same period a year earlier. Net income was $164.5 million, or $1.20 per share. Operating margin came to 17.93%, against -2.09% a year earlier. Free cash flow for the period was $40.6 million. Across the last 5 reported quarters, quarterly revenue has risen from $773.7 million in Q2 FY2025 to $1.29 billion in Q2 FY2026. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Alnylam Pharmaceuticals, Inc. are on the SentiSense financials page.
- Revenue
- $1.3B
- Net Income
- $164M
- EPS
- $1.23
- Total Assets
- $5.6B
- Operating Cash Flow
- $75M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $1.3B | $164M | $1.20 | 17.93% | $41M |
| Q1 FY2026 | $1.2B | $206M | $1.51 | 23.02% | $49M |
| Q4 FY2025 | $1.1B | $186M | $1.37 | 12.01% | $140M |
| Q3 FY2025 | $1.2B | $251M | $1.84 | 29.46% | $313M |
| Q2 FY2025 | $774M | -$66M | -$0.51 | -2.09% | $139M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $3.7B | $314M | $2.33 | 13.51% | $465M |
| FY2024 | $2.2B | -$278M | -$2.18 | -7.87% | -$43M |
| FY2023 | $1.8B | -$440M | -$3.52 | -15.43% | $42M |
Frequently asked questions
What was Alnylam Pharmaceuticals, Inc.'s revenue last quarter?
Alnylam Pharmaceuticals, Inc. reported revenue of $1.29 billion for Q2 FY2026, up 66.9% from the same period a year earlier.
Is Alnylam Pharmaceuticals, Inc. profitable?
Yes. Alnylam Pharmaceuticals, Inc. reported net income of $164.5 million for Q2 FY2026, a net margin of 12.74% on revenue.
How has Alnylam Pharmaceuticals, Inc.'s margin trended?
Operating margin was 17.93% in Q2 FY2026, compared with -2.09% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Alnylam Pharmaceuticals, Inc. generate?
Alnylam Pharmaceuticals, Inc. generated free cash flow of $40.6 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Alnylam Pharmaceuticals, Inc. on SentiSense, with up to forty quarters and twenty fiscal years of history.